The UK’s Medical Research Council (MRC) has awarded funds to Prof Helen McShane (University of Oxford) and Associate Prof Helen Fletcher (London School of Hygiene & Tropical Medicine) to set [...]
The new Spanish tuberculosis vaccine MTBVAC has received 12 million euros to carry out Phase 2a trials in new-borns and in adults in South Africa. read the press release
TBVAC2020 (a European consortium of TB R&D partners led by TBVI and funded by the EC) gives an update on its progress towards the development of new, safe and affordable TB vaccines – [...]
India’s research expertise, its manufacturing capacity, and the important role that India plays in global efforts to end the tuberculosis (TB) epidemic make it an exciting venue to host the 5th [...]
Nature News&Comment 22/07/2017 21:00 Not enough attention has been paid to vaccines in the quest to beat drug-resistant infections: read the editorial
Researchers at the University of Zaragoza (belonging to CIBERES) and the biopharmaceutical vaccine company Biofabri in Porrino, Spain, in partnership with the TuBerculosis Vaccine Initiative [...]
TBVI is pleased to announce the 3 winners of the young scientist award 2017. Each of these winners are outstanding scientist in the TB vaccine R&D field. TBVI wishes them a very successful [...]
As of 1 of March, Jelle Thole has joined TBVI full time as Director Product and Clinical Development. His major role will be to lead the Product & Clinical Development Team (P&CDT) of [...]
Unitat de Tuberculosi Experimental is part of a foundation for TB and within it, they have organised an art competition to raise funds. Please find attached the leaflet and check the website at [...]
EDCTP recently published new Calls for Proposals. For tuberculosis vaccine development, in particular the call “Vaccines for poverty-related diseases” is of interest to TB vaccine R&D [...]
Runderweg 6
8219 PK Lelystad
The Netherlands
Email: info@tbvi.eu
Phone: +31 320 277 550
